More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups
You may also be interested in...
EU Chamber Of Commerce Urges Bold Reforms On Market Access By China’s New Leaders
The European Chamber of Commerce in China calls on Beijing to break the grip of state-owned companies on market access and seize a “historic opportunity” of a leadership transition to open the economy.
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.